Gracell Bio jumps on positive myeloma drug data

Gracell Biotechnologies

13/06/2022 14:18

** Shares of China-based drug developer Gracell
Biotechnologies Inc  GRCL.O  up 16.4% at $3.84 premarket 
    ** Co is among the few gainers on the Nasdaq biotech index
 .NBI , amid a fall in U.S. stock index futures 
    ** None of the 29 patients with a type of myeloma in co's
study had any signs of cancer cells in the body after receiving
GRCL's cell therapy drug, Gracell says  urn:newsml:reuters.com:*:nPn1Y0DgQa
    ** Up to Friday's close, stock has declined ~45% this year 

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))